
Laure Dossus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8481741/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term weight change and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. International Journal of Epidemiology, 2022, 50, 1914-1926.	1.9	11
2	Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis. BMC Medicine, 2022, 20, 3.	5.5	41
3	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6
4	Determinants of Obesity and Metabolic Health in the Afghan Population: Protocol, Methodology, and Preliminary Results. Journal of Epidemiology and Global Health, 2022, 12, 113-123.	2.9	5
5	Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer. British Journal of Cancer, 2022, 126, 1301-1309.	6.4	22
6	Metabolically-Defined Body Size Phenotypes and Risk of Endometrial Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiology Biomarkers and Prevention, 2022, , .	2.5	4
7	Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis. BMC Medicine, 2022, 20, 125.	5.5	26
8	Circulating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohort. BMC Medicine, 2022, 20, 118.	5.5	7
9	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. Scientific Reports, 2022, 12, 6199.	3.3	2
10	Inflammatory potential of the diet and association with risk of differentiated thyroid cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. European Journal of Nutrition, 2022, 61, 3625-3635.	3.9	4
11	Weight change in middle adulthood and risk of cancer in the European Prospective Investigation into Cancer and Nutrition (<scp>EPIC</scp>) cohort. International Journal of Cancer, 2021, 148, 1637-1651.	5.1	23
12	Adiposity and Endometrial Cancer Risk in Postmenopausal Women: A Sequential Causal Mediation Analysis. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 104-113.	2.5	17
13	Antiplatelet Drug Use and Breast Cancer Risk in a Prospective Cohort of Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 643-652.	2.5	5
14	Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: a case–control study nested within the French E3N cohort. British Journal of Cancer, 2021, 124, 1734-1743.	6.4	27
15	Dietary intake of trans fatty acids and breast cancer risk in 9 European countries. BMC Medicine, 2021, 19, 81.	5.5	24
16	Metabolic signatures of greater body size and their associations with risk of colorectal and endometrial cancers in the European Prospective Investigation into Cancer and Nutrition. BMC Medicine, 2021, 19, 101.	5.5	24
17	Inflammatory potential of the diet and risk of breast cancer in the European Investigation into Cancer and Nutrition (EPIC) study. European Journal of Epidemiology, 2021, 36, 953-964.	5.7	8
18	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6

#	Article	IF	CITATIONS
19	Biomarkers of mammographic density in premenopausal women. Breast Cancer Research, 2021, 23, 75.	5.0	3
20	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7
21	Prospective analysis of circulating metabolites and endometrial cancer risk. Gynecologic Oncology, 2021, 162, 475-481.	1.4	23
22	Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women. BMC Medicine, 2021, 19, 186.	5.5	9
23	Are Circulating Immune Cells a Determinant of Pancreatic Cancer Risk? A Prospective Study Using Epigenetic Cell Count Measures. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2179-2187.	2.5	3
24	A New Pipeline for the Normalization and Pooling of Metabolomics Data. Metabolites, 2021, 11, 631.	2.9	15
25	Lifestyle correlates of eight breast cancer-related metabolites: a cross-sectional study within the EPIC cohort. BMC Medicine, 2021, 19, 312.	5.5	8
26	Mediation analysis of the alcoholâ€postmenopausal breast cancer relationship by sex hormones in the EPIC cohort. International Journal of Cancer, 2020, 146, 759-768.	5.1	14
27	Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2020, 146, 3267-3280.	5.1	14
28	Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women. Breast Cancer Research, 2020, 22, 118.	5.0	13
29	Body size, silhouette trajectory and the risk of breast cancer in a Moroccan case–control study. Breast Cancer, 2020, 27, 748-758.	2.9	6
30	Dietary and Circulating Fatty Acids and Ovarian Cancer Risk in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1739-1749.	2.5	15
31	The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3). Cancer Research, 2020, 80, 1210-1218.	0.9	35
32	Adult weight change and premenopausal breast cancer risk: A prospective pooled analysis of data from 628,463 women. International Journal of Cancer, 2020, 147, 1306-1314.	5.1	17
33	Theoretical potential for endometrial cancer prevention through primary risk factor modification: Estimates from the EPIC cohort. International Journal of Cancer, 2020, 147, 1325-1333.	5.1	6
34	Serologic markers of <i>Chlamydia trachomatis</i> and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the <scp>EPIC</scp> cohort. International Journal of Cancer, 2020, 147, 2042-2052.	5.1	26
35	Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1746-1754.	2.5	8
36	High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium. Cancer Research, 2019, 79, 5442-5451.	0.9	36

#	Article	IF	CITATIONS
37	Prospective analysis of circulating metabolites and breast cancer in EPIC. BMC Medicine, 2019, 17, 178.	5.5	79
38	Long-term airborne dioxin exposure and breast cancer risk in a case-control study nested within the French E3N prospective cohort. Environment International, 2019, 124, 236-248.	10.0	28
39	Cancers in France in 2015 attributable to insufficient physical activity. Cancer Epidemiology, 2019, 60, 216-220.	1.9	3
40	Association of a Priori-Defined Dietary Patterns with Anthropometric Measurements: A Cross-Sectional Study in Mexican Women. Nutrients, 2019, 11, 603.	4.1	8
41	Predicting Circulating CA125 Levels among Healthy Premenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1076-1085.	2.5	9
42	Development and validation of circulating CA125 prediction models in postmenopausal women. Journal of Ovarian Research, 2019, 12, 116.	3.0	12
43	Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and risk of in situ breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. BMC Medicine, 2019, 17, 221.	5.5	18
44	Healthy lifestyle and breast cancer risk: A case-control study in Morocco. Cancer Epidemiology, 2019, 58, 160-166.	1.9	17
45	Trends of serum phospholipid fatty acids over time in rural Uganda: evidence of nutritional transition?. British Journal of Nutrition, 2019, 121, 130-136.	2.3	2
46	Breast Cancer Risk After Recent Childbirth. Annals of Internal Medicine, 2019, 170, 22.	3.9	120
47	The impact of historical breastfeeding practices on the incidence of cancer in France in 2015. Cancer Causes and Control, 2018, 29, 325-332.	1.8	2
48	Tumorâ€associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. International Journal of Cancer, 2018, 143, 515-526.	5.1	18
49	Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 790-804.	2.5	6
50	Mitochondrial DNA copy number variation, leukocyte telomere length, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Breast Cancer Research, 2018, 20, 29.	5.0	44
51	Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: The EPIC study. International Journal of Cancer, 2018, 142, 1332-1342.	5.1	42
52	Life course evolution of body size and breast cancer survival in the E3N cohort. International Journal of Cancer, 2018, 142, 1542-1553.	5.1	6
53	Cancers in France in 2015 attributable to high body mass index. Cancer Epidemiology, 2018, 52, 15-19.	1.9	23
54	Ovarian cancer early detection by circulating <scp>CA</scp> 125 in the context of antiâ€ <scp>CA</scp> 125 autoantibody levels: Results from the <scp>EPIC</scp> cohort. International Journal of Cancer, 2018, 142, 1355-1360.	5.1	24

#	Article	IF	CITATIONS
55	Cancers related to lifestyle and environmental factors in France in 2015. European Journal of Cancer, 2018, 105, 103-113.	2.8	50
56	Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts. Breast Cancer Research, 2018, 20, 147.	5.0	24
57	Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort. BMC Cancer, 2018, 18, 1010.	2.6	9
58	Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women. JAMA Oncology, 2018, 4, e181771.	7.1	210
59	Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort. BMC Cancer, 2018, 18, 171.	2.6	75
60	Nonsteroidal antiâ€inflammatory drug use and breast cancer risk in a European prospective cohort study. International Journal of Cancer, 2018, 143, 1688-1695.	5.1	11
61	Menstrual and reproductive factors and risk of breast cancer: A case-control study in the Fez region, Morocco. PLoS ONE, 2018, 13, e0191333.	2.5	41
62	Dietary antioxidant capacity and all-cause and cause-specific mortality in the E3N/EPIC cohort study. European Journal of Nutrition, 2017, 56, 1233-1243.	3.9	45
63	Energy balance and obesity: what are the main drivers?. Cancer Causes and Control, 2017, 28, 247-258.	1.8	455
64	Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort. Clinical Cancer Research, 2017, 23, 4181-4189.	7.0	26
65	Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort. BMC Medicine, 2017, 15, 26.	5.5	21
66	Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort. Journal of Ovarian Research, 2017, 10, 20.	3.0	22
67	The Premenopausal Breast Cancer Collaboration: A Pooling Project of Studies Participating in the National Cancer Institute Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1360-1369.	2.5	23
68	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
69	Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium. Cancer Research, 2017, 77, 3951-3960.	0.9	48
70	Endometrial cancer risk prediction including serum-based biomarkers: results from the EPIC cohort. International Journal of Cancer, 2017, 140, 1317-1323.	5.1	28
71	Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort. Cancer Prevention Research, 2017, 10, 525-534.	1.5	29
72	Coffee Drinking and Mortality in 10 European Countries. Annals of Internal Medicine, 2017, 167, 236-247.	3.9	168

#	Article	IF	CITATIONS
73	Accuracy of two geocoding methods for geographic information system-based exposure assessment in epidemiological studies. Environmental Health, 2017, 16, 15.	4.0	29
74	Fiber intake modulates the association of alcohol intake with breast cancer. International Journal of Cancer, 2017, 140, 316-321.	5.1	12
75	Associations between serum lipids and breast cancer incidence and survival in the E3N prospective cohort study. Cancer Causes and Control, 2017, 28, 77-88.	1.8	34
76	Prediagnostic body size and breast cancer survival in the E3N cohort study. International Journal of Cancer, 2016, 139, 1053-1064.	5.1	7
77	A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. Clinical Cancer Research, 2016, 22, 4664-4675.	7.0	80
78	Healthy Lifestyle and Risk of Cancer in the European Prospective Investigation Into Cancer and Nutrition Cohort Study. Medicine (United States), 2016, 95, e2850.	1.0	55
79	Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. Journal of Clinical Oncology, 2016, 34, 2888-2898.	1.6	349
80	A treelet transform analysis to relate nutrient patterns to the risk of hormonal receptor-defined breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutrition, 2016, 19, 242-254.	2.2	26
81	An epidemiological model for prediction of endometrial cancer risk in Europe. European Journal of Epidemiology, 2016, 31, 51-60.	5.7	43
82	Heme Iron Intake, Dietary Antioxidant Capacity, and Risk of Colorectal Adenomas in a Large Cohort Study of French Women. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 640-647.	2.5	46
83	Vegetable and fruit consumption and the risk of hormone receptor–defined breast cancer in the EPIC cohort. American Journal of Clinical Nutrition, 2016, 103, 168-177.	4.7	48
84	A Nested Case–Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). PLoS Medicine, 2016, 13, e1001988.	8.4	76
85	Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2015, 136, 399-410.	5.1	36
86	Reproductive factors and risk of mortality in the European Prospective Investigation into Cancer and Nutrition; a cohort study. BMC Medicine, 2015, 13, 252.	5.5	53
87	Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study. Breast Cancer Research, 2015, 17, 49.	5.0	30
88	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279.	6.3	152
89	Reproductive and hormoneâ€related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort. International Journal of Cancer, 2015, 137, 1196-1208.	5.1	53
90	Investigation of Dietary Factors and Endometrial Cancer Risk Using a Nutrient-wide Association Study Approach in the EPIC and Nurses' Health Study (NHS) and NHSII. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 466-471.	2.5	42

#	Article	IF	CITATIONS
91	A statistical framework to model the meeting-in-the-middle principle using metabolomic data: application to hepatocellular carcinoma in the EPIC study. Mutagenesis, 2015, 30, gev045.	2.6	28
92	Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study. British Journal of Cancer, 2015, 113, 1622-1631.	6.4	29
93	Pre-diagnostic polyphenol intake and breast cancer survival: the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Breast Cancer Research and Treatment, 2015, 154, 389-401.	2.5	31
94	Risk of second primary malignancies in women with breast cancer: Results from the European prospective investigation into cancer and nutrition (EPIC). International Journal of Cancer, 2015, 137, 940-948.	5.1	70
95	Alcohol intake and breast cancer in the <scp>E</scp> uropean prospective investigation into cancer and nutrition. International Journal of Cancer, 2015, 137, 1921-1930.	5.1	65
96	Association of breast cancer risk <i>loci</i> with breast cancer survival. International Journal of Cancer, 2015, 137, 2837-2845.	5.1	33
97	Association of <i>CRP</i> genetic variants with blood concentrations of Câ€reactive protein and colorectal cancer risk. International Journal of Cancer, 2015, 136, 1181-1192.	5.1	69
98	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
99	Genetic risk variants associated with in situ breast cancer. Breast Cancer Research, 2015, 17, 82.	5.0	25
100	Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 951-961.	2.5	51
101	Estimated dietary dioxin exposure and breast cancer risk among women from the French E3N prospective cohort. Breast Cancer Research, 2015, 17, 39.	5.0	26
102	Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Research, 2015, 17, 37.	5.0	126
103	Pre-diagnostic concordance with the WCRF/AICR guidelines and survival in European colorectal cancer patients: a cohort study. BMC Medicine, 2015, 13, 107.	5.5	66
104	Dietary Intake of Acrylamide and Epithelial Ovarian Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 291-297.	2.5	16
105	The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. American Journal of Clinical Nutrition, 2015, 102, 1498-1508.	4.7	63
106	Healthy lifestyle and risk of breast cancer among postmenopausal women in the <scp>E</scp> uropean <scp>P</scp> rospective <scp>I</scp> nvestigation into <scp>C</scp> ancer and <scp>N</scp> utrition cohort study. International Journal of Cancer, 2015, 136, 2640-2648.	5.1	95
107	Fish consumption and mortality in the European Prospective Investigation into Cancer and Nutrition cohort. European Journal of Epidemiology, 2015, 30, 57-70.	5.7	39
108	Abstract 854: Ovarian cancer risk factors by histologic subtypes: evidence for etiologic heterogeneity. , 2015, , .		0

#	Article	IF	CITATIONS
109	A Genome-Wide "Pleiotropy Scan―Does Not Identify New Susceptibility Loci for Estrogen Receptor Negative Breast Cancer. PLoS ONE, 2014, 9, e85955.	2.5	8
110	Circulating 25-Hydroxyvitamin D3 in Relation to Renal Cell Carcinoma Incidence and Survival in the EPIC Cohort. American Journal of Epidemiology, 2014, 180, 810-820.	3.4	27
111	Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study. BMC Medicine, 2014, 12, 168.	5.5	178
112	Life in urban areas and breast cancer risk in the French E3N cohort. European Journal of Epidemiology, 2014, 29, 743-751.	5.7	24
113	Association between Melanocytic Nevi and Risk of Breast Diseases: The French E3N Prospective Cohort. PLoS Medicine, 2014, 11, e1001660.	8.4	12
114	Additive Interactions Between Susceptibility Single-Nucleotide Polymorphisms Identified in Genome-Wide Association Studies and Breast Cancer Risk Factors in the Breast and Prostate Cancer Cohort Consortium. American Journal of Epidemiology, 2014, 180, 1018-1027.	3.4	36
115	Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology, 2014, 60, 858-871.	7.3	175
116	Prediagnostic Intake of Dairy Products and Dietary Calcium and Colorectal Cancer Survival—Results from the EPIC Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1813-1823.	2.5	34
117	Insulinâ€like growth factor I and risk of breast cancer by age and hormone receptor status—A prospective study within the EPIC cohort. International Journal of Cancer, 2014, 134, 2683-2690.	5.1	52
118	Prediagnostic plasma testosterone, sex hormoneâ€binding globulin, IGFâ€l and hepatocellular carcinoma: Etiological factors or risk markers?. International Journal of Cancer, 2014, 134, 164-173.	5.1	33
119	Post-GWAS gene–environment interplay in breast cancer: results from the Breast and Prostate Cancer Cohort Consortium and a meta-analysis on 79 000 women. Human Molecular Genetics, 2014, 23, 5260-5270.	2.9	37
120	Pre-diagnostic anthropometry and survival after colorectal cancer diagnosis in Western European populations. International Journal of Cancer, 2014, 135, 1949-1960.	5.1	42
121	Dietary Intakes and Risk of Lymphoid and Myeloid Leukemia in the European Prospective Investigation into Cancer and Nutrition (EPIC). Nutrition and Cancer, 2014, 66, 14-28.	2.0	24
122	Risks of Endometrial Cancer Associated With Different Hormone Replacement Therapies in the E3N Cohort, 1992-2008. American Journal of Epidemiology, 2014, 180, 508-517.	3.4	76
123	Insulin-like Growth Factor-I and Risk of Differentiated Thyroid Carcinoma in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 976-985.	2.5	45
124	Prolactin Determinants in Healthy Women: A Large Cross-Sectional Study within the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2532-2542.	2.5	10
125	C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study. Cancer Causes and Control, 2014, 25, 533-539.	1.8	54
126	Active and passive cigarette smoking and breast cancer risk: Results from the EPIC cohort. International Journal of Cancer, 2014, 134, 1871-1888.	5.1	112

#	Article	IF	CITATIONS
127	Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status-Results from the EPIC cohort. International Journal of Cancer, 2014, 134, 1947-1957.	5.1	71
128	Thyroid-Stimulating Hormone, Thyroglobulin, and Thyroid Hormones and Risk of Differentiated Thyroid Carcinoma: The EPIC Study. Journal of the National Cancer Institute, 2014, 106, dju097.	6.3	84
129	Fruit and vegetable intake and cause-specific mortality in the EPIC study. European Journal of Epidemiology, 2014, 29, 639-652.	5.7	56
130	Dietary fat intake and risk of epithelial ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology, 2014, 38, 528-537.	1.9	16
131	Alcohol Consumption and Survival after a Breast Cancer Diagnosis: A Literature-Based Meta-analysis and Collaborative Analysis of Data for 29,239 Cases. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 934-945.	2.5	37
132	Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Research and Treatment, 2014, 145, 535-543.	2.5	82
133	Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). European Journal of Epidemiology, 2014, 29, 261-275.	5.7	56
134	Investigating sources of variability in metabolomic data in the EPIC study: the Principal Component Partial R-square (PC-PR2) method. Metabolomics, 2014, 10, 1074-1083.	3.0	40
135	Lifetime alcohol use and overall and cause-specific mortality in the European Prospective Investigation into Cancer and nutrition (EPIC) study. BMJ Open, 2014, 4, e005245-e005245.	1.9	81
136	Lifestyle, dietary factors, and antibody levels to oral bacteria in cancer-free participants of a European cohort study. Cancer Causes and Control, 2013, 24, 1901-1909.	1.8	20
137	Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study. BMC Cancer, 2013, 13, 584.	2.6	74
138	Menstrual and reproductive factors in women, genetic variation in <i>CYP17A1</i> , and pancreatic cancer risk in the European prospective investigation into cancer and nutrition (EPIC) cohort. International Journal of Cancer, 2013, 132, 2164-2175.	5.1	20
139	Alcohol drinking and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Annals of Epidemiology, 2013, 23, 93-98.	1.9	18
140	Anthropometric characteristics and risk of lymphoid and myeloid leukemia in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes and Control, 2013, 24, 427-438.	1.8	20
141	Physical activity and risk of breast cancer overall and by hormone receptor status: The European prospective investigation into cancer and nutrition. International Journal of Cancer, 2013, 132, 1667-1678.	5.1	72
142	Latitude and ultraviolet radiation dose in the birthplace in relation to menarcheal age in a large cohort of French women. International Journal of Epidemiology, 2013, 42, 590-600.	1.9	16
143	Plasma 25â€hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: A nested case–control study. International Journal of Cancer, 2013, 133, 1689-1700.	5.1	49
144	Height, age at menarche and risk of hormone receptorâ€positive and â€negative breast cancer: A cohort study. International Journal of Cancer, 2013, 132, 2619-2629.	5.1	62

#	Article	IF	CITATIONS
145	N-acetyltransferase 2 Phenotype, Occupation, and Bladder Cancer Risk: Results from the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2055-2065.	2.5	31
146	Hormonal, Metabolic, and Inflammatory Profiles and Endometrial Cancer Risk Within the EPIC Cohort—A Factor Analysis. American Journal of Epidemiology, 2013, 177, 787-799.	3.4	119
147	North–south gradients in plasma concentrations of B-vitamins and other components of one-carbon metabolism in Western Europe: results from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. British Journal of Nutrition, 2013, 110, 363-374.	2.3	23
148	Methylome Analysis and Epigenetic Changes Associated with Menarcheal Age. PLoS ONE, 2013, 8, e79391.	2.5	36
149	Prospective Study on Physical Activity and Risk of In Situ Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2209-2219.	2.5	14
150	Coffee and tea consumption and the risk of ovarian cancer: a prospective cohort study and updated meta-analysis. American Journal of Clinical Nutrition, 2012, 95, 1172-1181.	4.7	56
151	Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Research, 2012, 14, R76.	5.0	94
152	Determinants of age at menarche and time to menstrual cycle regularity in the French E3N cohort. Annals of Epidemiology, 2012, 22, 723-730.	1.9	37
153	The association of circulating adiponectin levels with pancreatic cancer risk: A study within the prospective EPIC cohort. International Journal of Cancer, 2012, 130, 2428-2437.	5.1	43
154	Sources of Pre-Analytical Variations in Yield of DNA Extracted from Blood Samples: Analysis of 50,000 DNA Samples in EPIC. PLoS ONE, 2012, 7, e39821.	2.5	31
155	A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). Annals of Human Biology, 2011, 38, 194-202.	1.0	72
156	Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes and Control, 2011, 22, 1075-1084.	1.8	51
157	Tumor necrosis factor (TNF)â€Î±, soluble TNF receptors and endometrial cancer risk: The EPIC study. International Journal of Cancer, 2011, 129, 2032-2037.	5.1	61
158	Pregnancy loss and risk of cardiovascular disease: a prospective population-based cohort study (EPIC-Heidelberg). Heart, 2011, 97, 49-54.	2.9	110
159	Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor–Positive and -Negative Breast Cancer: a Nested Case–Control Study. Cancer Prevention Research, 2011, 4, 1626-1635.	1.5	108
160	Concentrations of IGF-I and IGFBP-3 and Brain Tumor Risk in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2174-2182.	2.5	30
161	Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2010, 126, 2404-2415.	5.1	68
162	Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2010, 127, 442-451.	5.1	223

#	Article	IF	CITATIONS
163	Menopausal Hormone Therapy and Risk of Endometrial Carcinoma Among Postmenopausal Women in the European Prospective Investigation into Cancer and Nutrition. American Journal of Epidemiology, 2010, 172, 1394-1403.	3.4	117
164	Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortiumâ€. Human Molecular Genetics, 2010, 19, 3873-3884.	2.9	45
165	PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis, 2010, 31, 455-461.	2.8	68
166	Obesity, inflammatory markers, and endometrial cancer risk: a prospective case–control study. Endocrine-Related Cancer, 2010, 17, 1007-1019.	3.1	143
167	Abstract 1831: Cigarette smoking and risk of epithelial ovarian cancer according to histological subtypes: results from the EPIC study. , 2010, , .		0
168	Insulin-like Growth Factor-II Methylation Status in Lymphocyte DNA and Colon Cancer Risk in the Northern Sweden Health and Disease Cohort. Cancer Research, 2009, 69, 5400-5405.	0.9	30
169	The Association between Diet and Serum Concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1333-1340.	2.5	121
170	Validity of multiplex-based assays for cytokine measurements in serum and plasma from "non-diseased― subjects: Comparison with ELISA. Journal of Immunological Methods, 2009, 350, 125-132.	1.4	84
171	Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). BMC Cancer, 2009, 9, 257.	2.6	5
172	Lifestyle factors and serum androgens among 636 middle aged men from seven countries in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes and Control, 2009, 20, 811-821.	1.8	35
173	C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA,) Tj ETQq1 1 0.	784314 r 1.8	$gBT_{46}^{\prime}Overloc$
174	Vitamin D Receptor Polymorphisms and Breast Cancer Risk: Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 297-305.	2.5	82
175	Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Archives of Physiology and Biochemistry, 2009, 115, 86-96.	2.1	164
176	Nutrition, metabolic factors and cancer risk. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 551-571.	4.7	64
177	Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Carcinogenesis, 2008, 29, 1360-1366.	2.8	39
178	Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocrine-Related Cancer, 2008, 15, 485-497.	3.1	228
179	Human Chorionic Gonadotropin and Alpha-Fetoprotein Concentrations in Pregnancy and Maternal Risk of Breast Cancer: A Nested Case-Control Study. American Journal of Epidemiology, 2008, 168, 1284-1291.	3.4	27
180	IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE, 2008, 3, e2578.	2.5	106

#	Article	IF	CITATIONS
181	Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocrine-Related Cancer, 2007, 14, 81-90.	3.1	56
182	Genetic Variation at the <i>CYP19A1</i> Locus Predicts Circulating Estrogen Levels but not Breast Cancer Risk in Postmenopausal Women. Cancer Research, 2007, 67, 1893-1897.	0.9	140
183	Endogenous Androgens and Risk of Epithelial Ovarian Cancer: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 23-29.	2.5	54
184	Haplotype-Based Analysis of Common Variation in the Acetyl-CoA Carboxylase α Gene and Breast Cancer Risk: A Case-Control Study Nested within the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 409-415.	2.5	12
185	Plasma Adiponectin Levels and Endometrial Cancer Risk in Pre- and Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 255-263.	3.6	191
186	Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; Results from the European prospective investigation into cancer and nutrition. International Journal of Cancer, 2007, 120, 2656-2664.	5.1	96
187	Insulin resistance is inversely related to prostate cancer: A prospective study in Northern Sweden. International Journal of Cancer, 2007, 120, 2678-2686.	5.1	84
188	Risk of endometrial cancer in relationship to cigarette smoking: Results from the EPIC study. International Journal of Cancer, 2007, 121, 2741-2747.	5.1	46
189	Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: A study within the EPIC cohort. International Journal of Cancer, 2006, 118, 2832-2839.	5.1	132
190	Serum C-peptide levels and breast cancer risk: Results from the European prospective investigation into cancer and nutrition (EPIC). International Journal of Cancer, 2006, 119, 659-667.	5.1	104
191	No Association between Progesterone Receptor Gene +331G/A Polymorphism and Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1415-1416.	2.5	12
192	IGF-I, IGFBP-3 and breast cancer in young women: a pooled re-analysis of three prospective studies. European Journal of Cancer Prevention, 2005, 14, 493-496.	1.3	30
193	C-peptide, IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes and Control, 2005, 16, 561-572.	1.8	90
194	Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation into Cancer and Nutrition (EPIC). Journal of the National Cancer Institute, 2005, 97, 755-765.	6.3	391
195	Genetic Variation in the Growth Hormone Synthesis Pathway in Relation to Circulating Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Breast Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition Study. Cancer Epidemiology Biomarkers and Prevention. 2005. 14. 2316-2325.	2.5	33